Skip to main content
. 2024 Jan 20;10(2):e24867. doi: 10.1016/j.heliyon.2024.e24867

Table 3.

Association of osteoporosis with OSTEO18 in 389 uPROPHET patients.

Variable n/N (%) Unadjusted
Adjusted
Fully adjusted
OR (95 % CI) p-value OR (95 % CI) p-value OR (95 % CI) p-value
OSTEO18 score (categorized)
<-1 17/93 (18.3) 0.36 (0.23, 0.55) <0.0001 0.37 (0.24, 0.58) <0.0001 0.39 (0.25, 0.61) <0.0001
-1–0 27/107 (25.2) 0.54 (0.37, 0.79) 0.0016 0.54 (0.36, 0.79) 0.0017 0.53 (0.35, 0.79) 0.0017
0–1 48/97 (49.5) 1.57 (1.09, 2.24) 0.015 1.57 (1.09, 2.27) 0.016 1.57 (1.07, 2.29) 0.020
≥1 62/92 (67.4) 3.31 (2.26, 4.84) <0.0001 3.18 (2.14, 4.73) <0.0001 3.14 (2.08, 4.75) <0.0001
p for linear trend <0.0001 <0.0001 <0.0001
OSTEO18 score (continuous, +1) 154/389 (39.6) 2.07 (1.70, 2.50) <0.0001 2.02 (1.67, 2.46) <0.0001 2.03 (1.65, 2.49) <0.0001

Abbreviations: OR, odds ratio; CI, confidence interval. n/N indicates the number of participants with osteoporosis, the number of participants at risk in each category, and the corresponding percentages. In logistic regression, OSTEO18 was introduced as categorical and as continuously distributed variable. The categorized OSTEO18 score (<-1, -1-0, 0–1 and ≥1) was modeled by the deviation from mean coding, so that ORs express the relative risk compared with the average risk in the whole study population. Adjusted logistic models accounted for sex, age, eGFR, diabetes (yes vs no) and treatment with methylprednisolone (yes vs no). Fully adjusted logistic models additionally accounted for the time interval since HTx, ionized calcium, treatment with thiazides (yes vs no), tacrolimus (yes vs no) and cyclosporine (yes vs no).